Moderation of doxorubicin-induced nephrotoxicity in Wistar rats by aqueous leaf-extracts of Chromolaena odorata and Tridax procumbens

Catherine C. Ikewuchi, PhD\textsuperscript{a}, Mercy O. Ifeanacho, PhD\textsuperscript{b,*}, Jude C. Ikewuchi, PhD\textsuperscript{a}

Abstract

Background: The major drawback of doxorubicin’s use in chemotherapy is its toxicity on various organs including the kidneys. This study investigated the potential protective role of aqueous leaf-extracts of Chromolaena odorata and Tridax procumbens against nephrotoxicity induced by doxorubicin.

Methods: To this end, their impact on plasma biomarkers of kidney function, as well as renal lipid profile, biomarkers of oxidative stress, electrolyte profile and activities of renal ATPases was monitored in doxorubicin treated rats. Metformin (250 mg/kg body weight, orally) and the extracts (50, 75 and 100 mg/kg, orally) were daily administered for 14 days; while nephrotoxicity was induced with doxorubicin (15 mg/kg, intra-peritoneally), once on the 12th day of study.

Results: The plasma concentrations of creatinine, and urea; as well as the renal malondialdehyde, cholesterol, calcium and sodium concentrations in the Test control, were significantly ($P < .05$) higher than those of all the other groups. However, the renal concentrations of ascorbic acid, chloride, magnesium and potassium, and the renal activities of catalase, glutathione peroxidase, superoxide dismutase, Ca$^{2+}$-ATPase, Mg$^{2+}$-ATPase and Na$^+$,K$^+$-ATPase in the Test control were significantly ($P < .05$) lower than those of all the other groups.

Conclusions: Pre-treatment with the extracts and metformin boosted endogenous antioxidants, and prevented doxorubicin-induced renal damage, as indicated by the attenuation of doxorubicin-induced renal oxidative stress, as well as the attenuation of doxorubicin-induced adverse alterations in renal cholesterol, ATPases and electrolyte balance, and plasma biomarkers of kidney function, and keeping them at near-normal values.

Keywords: ATPases, cholesterol, Chromolaena odorata, doxorubicin, electrolytes, kidney function markers, oxidative stress, Tridax procumbens

Introduction

Doxorubicin’s toxicity affects various organs including the kidneys.\textsuperscript{1–6} Numerous studies suggest that doxorubicin-induced toxicity may be a consequence of oxidative stress, which results in oxidation and cross-linking of cellular thiols and membrane lipid peroxidation.\textsuperscript{1} Doxorubicin-induced oxidative stress in renal tissues is characterized by elevated malondialdehyde (a marker of lipid peroxidation) and lowered reduced glutathione levels\textsuperscript{4,7,8}; as well as lowered activities of catalase,\textsuperscript{2} glutathione peroxidase and superoxide dismutase.\textsuperscript{5,8,9} In addition to oxidative damage, doxorubicin toxicity also induces inflammatory changes in kidney tissues.\textsuperscript{8,10} Doxorubicin-induced nephrotoxicity causes increased capillary porousness and glomerular shrinking.\textsuperscript{8} It is characterized by increased plasma levels of creatinine, urea\textsuperscript{2,7} and uric acid,\textsuperscript{7} and increased plasma lactate dehydrogenase activity\textsuperscript{7}; as well as reduced renal Ca$^{2+}$-ATPase, Mg$^{2+}$-ATPase and Na$^+$,K$^+$-ATPase.\textsuperscript{1,8}

Studies suggest that the healing effect of metformin (a widely used anti-hyperglycaemic drug for type 2 diabetes mellitus) is facilitated by its effect on adenosine monophosphate-activated protein kinase in tissues.\textsuperscript{12,13} Numerous studies show that metformin lowers intracellular reactive oxygen species and regulates mitochondrial function.\textsuperscript{12,14,15} The beneficial effects of metformin on renal injury with different aetiologies have been reported,\textsuperscript{16} including the alleviation of diabetes-associated renal injury.\textsuperscript{12,17} Metformin ameliorates tubular injury by regulating oxidative stress and restoring biochemical alterations in renal tubules,\textsuperscript{12} as well as by anti-inflammatory and anti-apoptotic activities.\textsuperscript{14,18}

Studies have shown that doxorubicin-induced oxidative damage to the kidney can be mitigated or prevented by treatment with natural antioxidants;\textsuperscript{9,10,19} hence necessitating the investigation of various natural sources of antioxidants. The leaves of Chromolaena odorata and T procumbens are rich in potent antioxidants such as allicin, caffeic acid, ellagic acid, epicatechin, lycopene, naringenin, quercetin and silymarin.\textsuperscript{20–26} These antioxidants have been variously reported to exert nephro-

\textsuperscript{a} Department of Biochemistry, Faculty of Science, Faculty of Agriculture, University of Port Harcourt, P.M.B. 5323, Port Harcourt, Nigeria.

\textsuperscript{b} Corresponding author, Department of Food Science, Faculty of Agriculture, University of Port Harcourt, P.M.B. 5323, Port Harcourt, Nigeria. E-mail: mifeanacho@yahoo.com (Mercy O. Ifeanacho).

Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of PBJ-Associação Porto Biomedical/Porto Biomedical Society. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Porto Biomed. J. (2021) 6:1(e129)

Received: 18 June 2020 / Accepted: 3 January 2021
http://dx.doi.org/10.1097/j.pbj.0000000000000129
Materials and methods

Procurement of materials

Fresh samples of C odorata and T procumbens were collected from within the University of Port Harcourt, and were duly identified as earlier reported.20–26,34–39 Forty-five Wistar rats (weight 120–190 g) were obtained from the Animal House of Department of Pharmacology, University of Port Harcourt, Nigeria. All chemicals used were of analytical grade and products of Sigma-Aldrich, St Louis, MO, USA. The cholesterol, triglyceride and calcium kits were products of Random Laboratories Ltd, County Antrim, UK; the sodium and potassium kits were products of Atlas Medical, Cowley Rd, Cambridge, UK; while the chloride, magnesium, creatinine and urea kits were products of Agappe Diagnostics Switzerland, GmbH.

Preparation of extracts

The leaves were rid of dirt. Then 6 kg of C odorata and 5.5 kg of T procumbens were macerated. The resultant extracts were dried in a water bath, and their residues (127 and 116 g, respectively) were stored for use in the assay. The resultant leaf-extracts of C odorata and T procumbens (hereinafter referred to as COLE and TPLE, respectively), were weighed, reconstituted in distilled water and administered to the experimental animals, according to their groups’ dosages and their individual weights.

Experimental design and sample collection

All experimental procedures in this study were performed in accordance with the ethical guidelines for investigations using laboratory animals.54 The animals were weighed and sorted into 9 groups of 5 animals each, so that their average differences in weights were < 3 g.55 They were housed in cages at the Department of Pharmacology, and allowed food and water ad libitum. After 1 week acclimatization, the treatment commenced and lasted for 14 days. Diabmetin™ (metformin HCl) (dissolved in distilled water) was orally administered daily at 250 mg/kg body weight to the Metformin group. The extracts were administered via the same route at 50 mg/kg to COLE-50 mg (COLE) and TPLE-50 mg (TPLE); 75 mg/kg to COLE-75 mg (COLE) and TPLE-75 mg (TPLE); and 100 mg/kg to COLE-100 mg (COLE) and TPLE-100 mg (TPLE). The Normal and Test control groups received distilled water in place of the extract.

On day 12, doxorubicin was dissolved in normal saline and intra-peritoneally injected (15 mg/kg), into all the groups, except the Normal control which was given normal saline instead. The doxorubicin dosage was adopted from Song et al.56 The dosages of administration of C odorata extract was adopted and modified from Ikewuchi et al;22,24,25 that of T procumbens extract was from Ikewuchi et al;36,37 while that of metformin was from Zilinyi et al.57

The animals were sacrificed on day 14, under chloroform anaesthesia and blood samples were collected into heparin bottles; their kidneys were harvested, and their weights and sizes were documented.24 The blood samples were centrifuged at 1000 rpm for 10 min, and their plasma were removed and stored. The harvested organs were homogenized in distilled water (at 0.4 g per 5 mL), and the ensuing homogenates were stored for use in the assay. The kidney weights/sizes indices were determined using the formula below.58

\[
\text{Kidney weight or size index (\%)} = \frac{\text{Kidney weight (g) or kidney size (cm\textsuperscript{3})}}{\text{Body weight (g)}} \times 100
\]

Assay of biochemical parameters

The homogenates’ malondialdehyde concentrations were analysed according to the method of Gutteridge and Wilkins.59 The “sample tubes” contained 1 mL of glacial acetic acid, 1 mL of 1% thiobarbituric acid solution and 0.2 mL of sample. They were read at 532 nm, after zeroing the spectrophotometer with a blank containing 0.2 mL of distilled water instead. The ascorbic acid contents were estimated by iodine titration.60 Aliquot (1.0 mL) of the sample was added to 5 mL of reaction mix (31.746 mg% stearch in 1.243% (v/v) HCl); and titrated with iodine solution, until the appearance of a permanent blue colour. Catalase activities were according to Beers and Sizer.61 The “sample tubes” contained 2.50 mL of hydrogen peroxide, and 2.70 mL of distilled water was used to zero the spectrophotometer and absorbance read at 420 nm, exactly 1 minute after adding 0.20 mL of the sample. The “reference” contained 0.20 mL of distilled water in place of the sample. Superoxide dismutase activities were according to Misra and Fridovich.62 The “sample tubes” contained 0.1 mL of sample, 1.25 mL of 0.05 M carbonate buffer. They were equilibrated at room temperature, and 1.5 mL of distilled water was used to zero the spectrophotometer and absorbance read at 520 nm, exactly 1 minute after adding 0.15 mL of 0.3 M sodium azide. The “reference” contained 0.1 mL of distilled water in place of the sample. Glutathione peroxidase activities were according to Rotruck et al.63 The assay mixture containing 0.5 mL of sodium phosphate buffer (0.1 M, pH 7.4), 0.1 mL of 10 mM sodium azide, 0.2 mL of 4 mM reduced glutathione, 0.1 mL of 25 mM hydrogen peroxide, 0.5 mL sample, and 0.6 mL distilled water was incubated at 37°C for 3 min, before adding 0.5 mL 10% TCA. After centrifugation, the residual glutathione contents of the supernatants, was determined by adding 0.5 mL of the supernatants, 4.0 mL of 0.3 M disodium hydrogen phosphate solution and 1 mL of 0.01 M DTNB reagent, and reading at 412 nm, against a reagent blank containing only 4.5 mL phosphate solution and 1 mL DTNB reagent. Half millilitre of the standard (4 mM glutathione solution) was treated in a similar way. The activities of the ATPases were determined by the method of Hesketh et al.64 The quantity of inorganic phosphate was determined by the method of Fiske and Subbarow.65 The homogenates’ protein contents were determined by Lowry method.66

The calcium, chloride, cholesterol, magnesium, potassium, sodium and triglyceride contents of the homogenates were assayed according to the kits manufacturers’ instructions; except that homogenates were used instead of plasma. The assay procedures for the plasma creatinine and urea concentrations
were according to the kits manufacturers’ instructions. The urea to creatinine ratio was calculated with the formula below.67

\[
\text{Urea/creatinine ratio} = \frac{\text{Plasma urea concentration (mmol/L)}}{\text{Plasma creatinine concentration (mmol/L)}}
\]

**Determination of per cent protection**
The per cent protection of the kidneys were calculated with the formula below.21

\[
\text{Percent protection} = \frac{\text{Parameter}_{\text{Test control}} - \text{Parameter}_{\text{treatment}}}{\text{Parameter}_{\text{Test control}} - \text{Parameter}_{\text{normal control}}}
\]

**Statistical analysis of data**
Statistical calculations were carried out with the Excel 2010 (Data Analysis Add-in) software. All data are expressed as mean ± standard error of the mean (SEM), and were analysed using 1-way analysis of variance (1-way ANOVA). Significant difference of the means was determined using a post-hoc analysis involving LSD (least significant difference) test; with \( P < .05 \) considered statistically significant.

**Results**
The effects of aqueous leaf-extracts of \( C \) \( odorata \) and \( T \) \( procumbens \) on the kidney weight and size indices of doxorubicin treated rats is presented in Figure 1. The kidney weight index and kidney size index of Test control were not significantly different from those of all the other groups, except TPLE-50mg. The renal malondialdehyde concentration of Test control was significantly (\( P < .05 \)) higher than those of all the others (Table 1). The renal ascorbic acid concentration, and the renal catalase, glutathione peroxidase and superoxide dismutase activities of Test control were significantly (\( P < .05 \)) lower than those of all the others (Table 1). The plasma concentrations of creatinine, urea and blood urea nitrogen of Test control were significantly (\( P < .05 \)) higher than those of all the others (Fig. 2). However, the urea/creatinine ratio of Test control was significantly (\( P < .05 \)) lower than those of COLE-100mg and TPLE-100mg, but not significantly different from the others.

The renal cholesterol concentration of Test control was significantly (\( P < .05 \)) higher than those of all the others except

![Figure 1. Effects of aqueous leaf-extracts of \( C \) \( odorata \) and \( T \) \( procumbens \) on the kidney weight and size indices of doxorubicin treated rats. Values are mean ± SEM, \( n = 5 \) animals, per group. Bars in the same block with different superscript letters differ significantly at \( P < .05 \).](image)

### Table 1
**Effects of aqueous leaf-extracts of \( C \) \( odorata \) and \( T \) \( procumbens \) on renal biomarkers of oxidative stress of doxorubicin treated rats**

| Treatments    | Malondialdehyde (\( \mu \text{mol/mg protein} \)) | Ascorbic acid (\( \mu \text{g/mg protein} \)) | Glutathione peroxidase (\( \mu \text{mol/min/mg protein} \)) | Superoxide dismutase (units/mg protein) | Catalase (\( \mu \text{mol/min/mg protein} \)) |
|---------------|--------------------------------------------------|---------------------------------------------|-------------------------------------------------------------|------------------------------------------|-----------------------------------------------|
| Normal control| 1.221 ± 0.108\(^a\)                                | 18.881 ± 0.270\(^a\)                        | 0.192 ± 0.004\(^a\)                                         | 0.503 ± 0.056\(^a\)                       | 3.382 ± 0.118\(^a\)                            |
| Test control  | 1.894 ± 0.093\(^b\)                                | 7.925 ± 0.030\(^b\)                         | 0.137 ± 0.008\(^b\)                                         | 0.281 ± 0.032\(^b\)                       | 1.646 ± 0.083\(^b\)                            |
| Metformin     | 1.157 ± 0.090\(^b,c\)                              | 12.838 ± 0.222\(^c\)                        | 0.210 ± 0.002\(^b,c\)                                       | 0.754 ± 0.042\(^b,c\)                     | 3.412 ± 0.313\(^b,c\)                          |
| COLE-50mg     | 1.199 ± 0.062\(^a,b\)                              | 15.324 ± 0.227\(^b\)                        | 0.194 ± 0.007\(^b\)                                         | 0.554 ± 0.036\(^b\)                       | 3.399 ± 0.281\(^b\)                            |
| COLE-75mg     | 1.122 ± 0.105\(^a\)                                | 15.580 ± 0.248\(^b\)                        | 0.171 ± 0.004\(^a\)                                         | 0.647 ± 0.038\(^a\)                       | 2.964 ± 0.100\(^a\)                            |
| COLE-100mg    | 1.003 ± 0.059\(^a\)                                | 9.331 ± 0.177\(^a\)                         | 0.184 ± 0.007\(^a\)                                         | 0.787 ± 0.029\(^a\)                       | 3.607 ± 0.104\(^a\)                            |
| TPLE-50mg     | 1.132 ± 0.042\(^a\)                                | 9.402 ± 0.157\(^a\)                         | 0.168 ± 0.002\(^a\)                                         | 0.687 ± 0.025\(^a\)                       | 3.001 ± 0.231\(^a\)                            |
| TPLE-75mg     | 1.245 ± 0.140\(^a\)                                | 8.603 ± 0.036\(^a\)                         | 0.177 ± 0.003\(^a\)                                         | 0.736 ± 0.068\(^a\)                       | 3.467 ± 0.086\(^a\)                            |
| TPLE-100mg    | 0.946 ± 0.085\(^a\)                                | 10.687 ± 0.275\(^b\)                        | 0.187 ± 0.002\(^a\)                                         | 0.719 ± 0.061\(^a\)                       | 4.103 ± 0.238\(^a\)                            |

Values are mean ± SEM, \( n = 5 \). Values in the same column with different superscript letters differ significantly at \( P < .05 \).
Metformin (Table 2). The renal triglyceride concentration of Test control was not significantly different from those of all the others. The Mg$^{2+}$-ATPase, Na$^+$,K$^+$-ATPase and Ca$^{2+}$-ATPase activities of Test control were significantly ($P < .05$) lower than those of all the other groups (Table 2). As shown in Table 3, the renal chloride, magnesium and potassium concentrations of Test control were significantly ($P < .05$) lower; while the calcium and sodium concentrations were significantly ($P < .05$) higher than those of all the other groups. The administration of the extracts and metformin prevented the doxorubicin-induced renal damage, as indicated by the attenuation of doxorubicin-induced adverse alterations in the plasma markers of renal functions/integrity, and renal markers of oxidative stress, and caused a subsequent protection towards normalization. The administration of the extracts also prevented the doxorubicin-induced reduction in activities of renal ATPases, and caused a subsequent protection towards normalization. These protections have been presented in Table 4 in the form of per cent protection of the parameters by the different test treatments.

**Discussion**

One of the major contributors to doxorubicin toxicity is oxidative stress, which leads to membrane lipid peroxidation, and

![Figure 2](image)

**Figure 2.** Impact of aqueous leaf-extracts of *C odorata* and *T procumbens* on plasma biomarkers of kidney function of doxorubicin treated rats. Values are mean±SEM, n=5. Bars in the same block with different superscript letters differ significantly at $P < .05$. *Has no unit.

### Table 2

Effects of aqueous leaf-extracts of *C odorata* and *T procumbens* on renal lipid profiles and ATPase activities of doxorubicin treated rats

| Treatments   | Lipid profile (mmol/mg protein) | ATPase activities (mmol/min/mg protein) |
|--------------|---------------------------------|----------------------------------------|
|              | Triglyceride | Cholesterol | Mg$^{2+}$-ATPase | Na$^+$,K$^+$-ATPase | Ca$^{2+}$-ATPase |
| Normal control | 0.237 ± 0.043$^a$ | 0.231 ± 0.056$^a$ | 3.721 ± 0.353$^b$ | 15.881 ± 1.601$^a$ | 1.468 ± 0.081$^b$ |
| Test control  | 0.306 ± 0.079$^c$ | 0.459 ± 0.052$^c$ | 1.965 ± 0.129$^a$ | 7.973 ± 1.250$^b$ | 0.697 ± 0.058$^a$ |
| Metformin     | 0.250 ± 0.023$^a$ | 0.401 ± 0.022$^b$ | 3.555 ± 0.212$^c$ | 28.399 ± 1.210$^b$ | 1.713 ± 0.068$^c$ |
| COLE-50mg     | 0.212 ± 0.048$^b$ | 0.219 ± 0.049$^a$ | 13.060 ± 0.930$^d$ | 16.503 ± 1.928$^a$ | 1.143 ± 0.089$^d$ |
| COLE-75mg     | 0.216 ± 0.025$^a$ | 0.185 ± 0.045$^d$ | 4.257 ± 0.292$^c$ | 19.626 ± 2.474$^a$ | 1.656 ± 0.085$^f$ |
| COLE-100mg    | 0.169 ± 0.051$^e$ | 0.252 ± 0.050$^e$ | 8.326 ± 0.481$^b$ | 16.178 ± 2.033$^a$ | 1.012 ± 0.087$^e$ |
| TPLE-50mg     | 0.241 ± 0.040$^a$ | 0.243 ± 0.049$^f$ | 5.565 ± 0.182$^d$ | 17.365 ± 2.198$^b$ | 1.297 ± 0.051$^e$ |
| TPLE-75mg     | 0.195 ± 0.051$^f$ | 0.174 ± 0.059$^e$ | 4.192 ± 0.409$^b$ | 16.608 ± 2.579$^a$ | 1.908 ± 0.086$^f$ |
| TPLE-100mg    | 0.233 ± 0.050$^b$ | 0.202 ± 0.070$^a$ | 5.853 ± 0.499$^f$ | 21.522 ± 2.274$^a$ | 1.420 ± 0.074$^e$ |

Values are mean±SEM, n=5. Values in the same column with different superscript letters differ significantly at $P < .05$. 

Ikewuchi et al Porto Biomed. J. (2021) 6:1
and oxidation and cross-linking of cellular thiols. The doxorubicin administration produced oxidative stress in this study, is supported by the elevated renal malondialdehyde and lowered renal ascorbic acid levels, as well as the reduced renal activities of catalase, glutathione peroxidase and superoxide dismutase, observed in the Test control group. This result is in consonance with earlier reports. Pre-treatment with the extracts and metformin attenuated the doxorubicin-induced oxidative stress, by lowering the renal malondialdehyde and raising the ascorbic acid levels, and activities of catalase, glutathione peroxidase and superoxide dismutase. This antioxidant protective effect is in agreement with the reports of the glutathione peroxidase and superoxide dismutase. This antioxidant protective effect is in agreement with the reports of the glutathione peroxidase and superoxide dismutase. This antioxidant protective effect is in agreement with the reports of the glutathione peroxidase and superoxide dismutase. This antioxidant protective effect is in agreement with the reports of the glutathione peroxidase and superoxide dismutase.

In this study, induction of oxidative stress by doxorubicin raised plasma urea and creatinine levels. This is in line with other reports of doxorubicin-induced elevation in plasma creatinine and urea levels. Plasma biomarkers such as creatinine and urea concentrations are usually monitored to evaluate glomerular function, because of their inverse relationship with the latter. Therefore, the reduction in the plasma creatinine and urea levels, produced by the extracts, is suggestive of their capacity to protect the nephrons from doxorubicin-induced damage, and thus preserve the functional capacity of the glomerular filtration apparatus. The extracts’ lowering of plasma creatinine, blood

| Treatments                  | Calcium (µg/mg protein) | Chloride (µmol/mg protein) | Magnesium (µg/mg protein) | Potassium (µmol/mg protein) | Sodium (µmol/mg protein) |
|-----------------------------|-------------------------|-----------------------------|---------------------------|-----------------------------|--------------------------|
| Normal control              | 9.557 ± 0.197a<sup>c</sup> | 11.307 ± 0.262<sup>d</sup>  | 3.894 ± 0.026<sup>d</sup>  | 0.799 ± 0.020<sup>d</sup>  | 7.090 ± 0.831<sup>c</sup>  |
| Test control                | 13.867 ± 0.487<sup>c</sup> | 6.877 ± 0.076<sup>c</sup>  | 3.072 ± 0.027<sup>d</sup>  | 0.416 ± 0.017<sup>c</sup>  | 12.449 ± 0.443<sup>c</sup>  |
| Metformin                   | 9.172 ± 0.462<sup>b</sup><sup>d</sup> | 8.914 ± 0.266<sup>c</sup>  | 5.876 ± 0.030<sup>c</sup>  | 0.474 ± 0.010<sup>d</sup>  | 7.138 ± 0.163<sup>c</sup>  |
| COLE-50mg                   | 10.027 ± 0.434<sup>c</sup> | 12.882 ± 0.387<sup>c</sup> | 5.083 ± 0.041<sup>d</sup>  | 0.561 ± 0.012<sup>e</sup>  | 8.017 ± 0.220<sup>b</sup>  |
| COLE-75mg                   | 8.644 ± 0.508<sup>b</sup><sup>c</sup> | 8.597 ± 0.338<sup>b</sup>  | 4.626 ± 0.040<sup>d</sup>  | 0.471 ± 0.016<sup>d</sup>  | 7.521 ± 0.144<sup>c</sup>  |
| COLE-100mg                  | 8.163 ± 0.326<sup>c</sup> | 14.603 ± 0.323<sup>c</sup> | 3.851 ± 0.024<sup>c</sup>  | 0.606 ± 0.009<sup>f</sup>  | 8.109 ± 0.382<sup>e</sup>  |
| TPLE-50mg                   | 8.197 ± 0.480<sup>c</sup> | 13.191 ± 0.362<sup>b</sup> | 5.250 ± 0.047<sup>d</sup>  | 0.734 ± 0.029<sup>c</sup>  | 8.107 ± 0.315<sup>e</sup>  |
| TPLE-75mg                   | 8.176 ± 0.406<sup>b</sup> | 8.245 ± 0.071<sup>d</sup>  | 3.732 ± 0.026<sup>d</sup>  | 0.685 ± 0.008<sup>b</sup>  | 6.516 ± 0.188<sup>e</sup>  |
| TPLE-100mg                  | 8.718 ± 0.263<sup>b</sup> | 14.040 ± 0.442<sup>d</sup> | 5.056 ± 0.041<sup>d</sup>  | 0.646 ± 0.027<sup>d</sup>  | 8.161 ± 0.326<sup>c</sup>  |

Values are mean ± SEM, n=5. Values in the same column with different superscript letters differ significantly at P<.05.
urea nitrogen and urea may be due to their content of caffeic and chlorogenic acids, both of which had been reported to decrease plasma levels of kidney markers to near-normal levels.24,75

In this study, doxorubicin treatment caused significant increase in renal cholesterol and triglycerides. This is in conformity with reports of doxorubicin-induced increases in renal cholesterol and triglycerides levels in both humans and experimental animals.76,77 However, pre-treatment with the extracts prevented this cholesterol and triglyceride accumulation. This effect may be sequel to the presence in the extracts, of chlorogenic acid, ellagic acid, naringenin and quercetin,21,22,23,26,78 which are known to lower adiposity and triglyceride contents,9,9,45 and modulate hepatic lipids.82,83 The renal cholesterol lowering activity of the extracts has serious implications on the integrity and function of the renal cell membranes. This is because studies have shown that the level of cholesterol in membranes correlates inversely with the fluidity of membranes.86–88 Cholesterol plays a major role in the control of the structure and dynamics of the lipid bilayer (fluidity); and therefore, can modulate the activities of various membrane transporters such as Ca2+-ATPase, Mg2+-ATPase, Na+,K+-ATPase and Ca2+ channels in various cells.89–92

In this study, the administration of doxorubicin produced significantly lowered Na+,K+-ATPase, Mg2+-ATPase and Ca2+ -ATPase activities in the renal tissues. This corroborated earlier report of doxorubicin-induced significant reductions in renal Na+,K+-ATPase, Ca2+-ATPase and Mg2+-ATPase activities.1,11 It however, negates the report by Ma et al,93 of doxorubicin-induced significant activation of Na+,K+-ATPase activity. Pre-treatment with the extracts raised the renal activities of Na+,K+-, Mg2+- and Ca2+-ATPases. The extracts’ ability to increase ATPase activities may be due to the presence of any one or both of ascorbic acid and epicatechin, earlier reported in them. According to Kumar et al94 ascorbic acid or epicatechin prevents oxidative stress-induced lowering of Ca2+-ATPase and Na+,K+-ATPase activities.

The extracts may have improved Na+,K+-ATPase, Ca2+ -ATPase and Mg2+-ATPase activities by preventing doxorubicin-induced lipid peroxidation or oxidative stress and cholesterol loading, thereby preventing the subsequent oxidative modification of the enzymes, as well as the modification of the membrane lipid environment and fluidity of the plasma membrane. They may have accomplished the augmentation of ATPase activities via any one or a combination of 2 or more of the following. Firstly, the direct interaction between the phytoconstituents in the extracts and the enzymes may have resulted in changes in the enzymes’ structure, and consequently changes in its activity, or protection of the enzymes’ sulphhydril groups,95,96 from interacting with doxorubicin or its metabolites, or from oxidation and subsequent formation of disulphide bridges. Secondly, by reducing the concentration of free radicals and reactive oxygen species, and consequently, reducing oxidative stress and lipid peroxidation.94,97–101 Thirdly, by the impact of their phytoconstituents in preventing increased lipid order and lowered membrane fluidity;90,91,97,101–104 which are products of increased cholesterol content and lipid peroxidation.86,105 Lastly, by the impact of the phytoconstituents in the extracts, on the lipids of the plasma membrane which in turn may have led to changes in the surrounding lipid environment or protein-lipid interactions.90,91,97,101,106–108

Therefore, the reduction in lipid peroxidation (or oxidative stress) and/or tissue cholesterol, as well as protection of the enzymes’ sulphhydril groups may be responsible for the extracts ability to increase renal Na+,K'-ATPase, Ca2+-ATPase and Mg2-ATPase activities. The significance of these modulations of renal ATPases cannot be overemphasized, given that Na+,K'-ATPase is important in controlling the reabsorption of Na+ and water in the kidney109,110, while Ca2+-ATPase is involved in renal active Ca2+ transport.111,112

Consequently, the elevated concentrations of renal calcium and sodium, as well as the lowered chloride, magnesium and potassium, induced by doxorubicin in this study, is reflective of compromised membranes of the renal tissues. However, pre-treatment with the extracts prevented the doxorubicin-induced electrolyte imbalance. This ability to modulate renal electrolytes may also be due to the presence of chlorogenic acid, which had been reported to improve mineral pool distribution in plasma, spleen and liver.113 The reduction of renal cholesterol content may have resulted in the reduction in renal calcium content by the extracts. This is in view of the reports that decrease in cholesterol content of plasma membranes leads to decreased Ca2+ influx through the Ca2+ channel in plasma membranes, which results in decreases in intracellular calcium, and vice versa.87,114–116 Reduction in membrane cholesterol has also been reported to stimulate the activities of Ca2+-, Mg2+- and Na+,K'-ATPases.87,117,118 which modulates the transport of calcium, magnesium, potassium and sodium ions across plasma membranes,119–127 and by extension, intracellular electrolyte balance. This suggests that modulation of renal calcium, sodium and magnesium levels by the extracts may have been achieved via an interplay of the modulation of renal cholesterol concentration and Ca2+-, Na+,K'- and Mg2+-ATPases.

Therefore, taken together, we can safely posit that the extracts acted by boosting endogenous antioxidant and modifying the micro-viscosity of renal membrane via lowering cholesterol levels, and reducing doxorubicin-induced oxidative stress (lipid peroxidation) and protein sulphydryl modification; and that the ensuing increased fluidity caused improved Ca2+-, Mg2+- and Na+,K'-ATPase activities. The subsequent improvement in ion transport then led to improved electrolyte balance, especially, offsetting doxorubicin-induced calcium overload. This may be the mechanism of nephroprotective activities of the extracts. This therefore, is a suggestion of their prospect as resources for prevention or management of doxorubicin-induced renal toxicity.

Data accessibility statement
All relevant data are within the paper.

Competing interests
The authors have declared that no competing interests exist.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References
[1] Malarkodi DP, Balachandar AV, Varalakshmi P. The influence of lipoic acid on adriamycin induced nephrotoxicity in rats. Mol Cell Biochem. 2003;247:15–22.
[2] Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology. 2006;218:164–171.
[16] Eisenreich A, Leppert U. Update on the protective renal effects of metformin in diabetic nephropathy. Curr Med Chem. 2017;24:3397.

[17] Ravindran S, Kuruvilla V, Wilbur K, Munusamy S. Nephroprotective pathway: an in vitro study. PLoS One. 2014;9:e104888.

[18] Rizk FH, El Saadany AA, Dawood L, et al. Metformin ameliorated decreased ATPase activity in Adriamycin nephrosis is independent of mitochondrial function. Liver Res. 2020;https://doi.org/10.1016/j.liver.2019.128.

[19] Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants. 2015;4:204.

[20] Ikewuchi JC, Ikewuchi CC, Igboh MN. Chemical properties of green tea infusion and epicatechin on doxorubicin-induced cytoxicity in male albino rats. Int J Pharm Sci Res. 2019;10:1000–1014.

[21] Ikewuchi JC, Ikewuchi CC, Enuneku EC, et al. Alteration of blood pressure indices and pulse rates by an aqueous extract of the leaves of Chromolaena odorata (L) King and Robinson (Asteraceae). Pac J Sci Technol. 2013;14:362.

[22] Ikewuchi JC, Ikewuchi CC. Anti-cholesterolemic effect of aqueous extract of Tridax procumbens Linn (Asteraceae). Pac J Sci Technol. 2012;13:348–358.

[23] Ikewuchi JC, Ikewuchi CC, Iteanacho MO. Analysis of the phytochemical composition of the leaves of Chromolaena odorata Linn (Asteraceae) against protected against carbon tetrachloride induced hepatic cholestasis-associated nephropathy through regulating oxidative stress and mitochondrial function. Liver Res. 2020;https://doi.org/10.1016/j.livres.2020.12.001.

[24] Ikewuchi JC, Ikewuchi CC, Igboh MN. Chemical profile of Tridax procumbens Linn. Pak J Nutr. 2009;8:548–550.

[25] Ikewuchi JC. An aqueous extract of the leaves of Tridax procumbens Linn (Asteraceae) protected against cardiac oxidative stress and mitochondrial damage in rat heart. Asian J Pharm Sci. 2012;7:321–325. doi: 10.1016/j.ajps.2011.10.003.

[26] Ikewuchi JC, Ikewuchi CC, Iteanacho MO. Phytochemical composition of Tridax procumbens Linn leaves: Potential as a functional food. Food Nutr Sci. 2015;6:992–1004.

[27] Yagmurca M, Erdogan H, Iraz M, et al. Caffeic acid phenethyl ester as a protective agent against doxorubicin nephropathy in rats. Clin Chim Acta. 2008;395:25–34.

[28] Gnanasundari M, Pari L. Impact of naringenin on oxytetracycline-mediated oxidative damage in kidney of rats. Renal Fail. 2006;28:599–605.

[29] El-Shityan NA, El-Haggar S, El-Desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008;46:2422–2428.

[30] Renugadevi J, Prabu SM. Naringenin protects against cadmium-induced oxidative renal dysfunction in rats. Toxicology. 2009;256:128–134.

[31] El-Kashef DH, El-Kenawi AE, Suddek GM, et al. Protective effect of allicin against gentamicin-induced nephrotoxicity in rats. Int Immunopharmacol. 2015;29:679–686.

[32] Omar WM, Raslan YA, Amany AEA, et al. The ameliorative effect of ellagic acid and rosemarinic acid against cardio-nephrotoxicity induced by doxorubicin in rats. Int J Sci Res Pub. 2016;6:249–256.

[33] Ikewuchi JC, Ikewuchi CC. Alteration of plasma lipid profile and atherogenic indices of cholesterol loaded rats by Tridax procumbens Linn: Implications for the management of obesity and cardiovascular diseases. Biochembiometrics. 2009;2:91–99.

[34] Ikewuchi JC, Ikewuchi CC, Onwuka FC. Weight reducing and anti-inflammatory effects of aqueous extract of Tridax procumbens against D-galactosamine/lipopolysaccharide-induced hepatitis in rats. Pak J Pharm Sci. 2018;7:867–868.

[35] Ikewuchi JC, Ikewuchi CC, Onwuka EN, Uwakwe AA, et al. Weight reducing and hypcholesterolemic effect of aqueous extract of the leaves of Tridax procumbens Linn on sub-chronic salt-loaded rats. Int J Biol Chem Sci. 2011;5:680–687.

[36] Ikewuchi JC, Ikewuchi CC. Moderation of haematological indices, plasma electrolytes and markers of hepato-renal function in sub-chronic salt-loaded rats by Tridax procumbens Linn (Asteraceae). Pac J Sci Technol. 2013;14:362–369.

[37] Ikewuchi JC, Ikewuchi CC, Onyike EN, Uwakwe AA, et al. Effect of aqueous extract of the leaves of Tridax procumbens Linn on blood pressure components and pulse rates of sub chronic salt-loaded rats. Pac J Sci Technol. 2011;12:381–389.

[38] Ikewuchi JC, Ikewuchi CC, Onyike EN, Uwakwe AA, et al. Effect of aqueous extract of the leaves of Tridax procumbens Linn on plasma electrolytes of salt-loaded rats. Pak J Nutr. 2010;9:103–105.

[39] Ikewuchi JC, Ikewuchi CC. Anti-cholesterolemic effect of aqueous extract of Tridax procumbens Linn on pressure induced rats. Pharmacogn Mag. 2018;14:427–435.

[40] Ikewuchi JC, Onyike EN, Uwakwe AA, et al. Effect of aqueous extract of the leaves of Tridax procumbens Linn on sub-chronic salt-loaded rats. Int J Biol Chem Sci. 2011;5:680–687.

[41] Ikewuchi JC, Ikewuchi CC. Prevention of doxorubicin-induced dyslipidaemia, plasma oxidative stress and electrolytes imbalance in Wistar rats by aqueous leaf-extracts of Chromolaena odorata and Tridax procumbens. Scientific Afr. J. 2014;6:1050–1059.

[42] Ravikumar V, Shivashangari KS, Devaki T. Hepatoprotective activity of Tridax procumbens against r-galactosamine/hypoliposaccharide-induced hepatitis in rats. J Ethnopharmacol. 2005;101:55–60.

[43] Ikewuchi JC. Alteration of plasma biochemical, haematological and ocular oxidative indices of alloxaan induced diabetic rats by aqueous extract of Tridax procumbens Linn (Asteraceae). EXCLI J. 2012;11:291–308.

[44] Onkaramurthy M, Veerarpur VP, Thippeswamy BS, et al. Anti-diabetic and anti-cataract effects of Chromolaena odorata Linn., in streptozotocin-induced diabetic rats. J Ethnopharmacol. 2013;145:363–372.

[45] Palanisamy P, Chandra RM, Jaykar B, et al. Evaluation of hepatoprotective activity of whole plant extract of Chromolaena odorata and Tridax procumbens. Scientific Afr. J. 2014;6:1050–1059.

[46] Vishnu PP, Srinivasa RA. Evaluation of anticancer activity of Tridax procumbens leaf extracts on A549 and Hep G2 cell lines. Asian J Pharm Sci. 2014;9:55–60.

[47] Adedapo AA, Oyagbemi AA, Fagbouhn OA, et al. Evaluation of the anticancer properties of the methanol leaf extract of Chromolaena odorata on HT-29 cell line. J Pharmacogn Phytochem. 2016;5:52–57.

[48] Sojitha R, Sharmila R. Phytochemical analysis and in vitro anticanancer activity of Tridax procumbens Linn. World J Pharmaceut Res. 2018;7:867–878.
Bhargava D, Mondal CK, Shivapuri JN, et al. Antioxidant properties of the leaves of *Chromolaena odorata* Linn. *J Institute Med*. 2013;35:53–56.

Andrani Y, Xuan TD, Quy TN, Minh TN, Van TM, Viet TD. Anthyperuricaemia, antioxidant, and antibacterial activities of *Tridax procumbens* L. *Foods*. 2019;8:21. doi: 10.3390/foods8010021.

Putri DA, Fattamawati S. A new flavonone as a potent antioxidant isolated from *Chromolaena odorata* L. leaves. *Evid Based Complement Alternat Med*. 2019;2019:1453612. doi: 10.1155/2019/1453612.

Cui HX, Zhang LS, Yan HG, et al. Constituents of flavonoids from *Tridax procumbens* L. and antioxidant activity. *Phyco Mag*. 2020;20:1601–205. doi: 10.1007/s13314-020-00238-0.

Sved A, Benit N, Ayyousef AA, Alqasim A, et al. The cardioprotective effect of *Chromolaena odorata* L. leaf and its active compounds on myocardial infarction: a clinical and experimental study. *Ejurnal*. 2010;1:367–371.

National Research CouncilGuide for the Care and Use of Laboratory Animals. 8th ed.*Washington, DC:* *The National Academies Press*; 2011.

Protein quality evaluation: Report of Joint FAO/WHO Expert Consultation. *FAO Food and Nutrition Paper* 51. *Rome: Food and Agriculture Organization of the United Nations*; 1991.

Song S, Chiu J, Liang H, et al. Protective effects of Dioscin against doxorubicin-induced hepatotoxicity via regulation of Sirt1/FOXO1/FoxO1 signal. *Front Pharmacol*. 2019;10:0930. doi: 10.3389/fphar.2019.01030.

Zilinyi R, Czompa A, Czegledi A, et al. The role of superoxide anion in the auto-oxidation of epinephrine and a single assay for superoxide dismutase: the role of autophagy. *Molecules*. 2018;23:138. doi: 10.3390/molecules23051184.

Ifeanacho MO, Ikewuchi CC, Ikewuchi JC. Comparative study on the vitamin composition of some common Nigerian medicinal plants. *Pac J Sci Technol*. 2009;10:1:367–71.

Ikewuchi CC, Ikewuchi JC. Anti-diabetic effect of a *Zingiber officinale* root extract on alloxan-induced diabetic rabbits. *Endocr Metab Disord*. 2012;23:051184. doi: 10.4236/emd.2012.23051184.

Ikewuchi CC, Ikewuchi JC. Comparative study on the vitamin composition of some common Nigerian medicinal plants. *Pac J Sci Technol*. 2009;10:1:367–71.

Ikeaka MO, Ikewuchi JC. Antihyperuricemia, antioxidant, and antibacterial activities of *Tridax procumbens* L. *J Adv Pharm Technol Res*. 2016;7:37–42.

Cho KW, Kim YO, Andrade JE, Burgess JR, Kim YC. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor alpha protein expression and decreases plasma triglyceride and adiposity in rats. *Eur J Nutr*. 2011;50:81–88.

Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavans and naringenin, on metabolic syndrome and their mechanisms of action. *Adv Nutr*. 2014;5:404–417.

Okla M, Kang I, Kim DM, et al. Ellagic acid modulates lipid accumulation in primary human adipocytes and human hepatoma Huh7 cells via discrete mechanisms. *J Nutr Biochem*. 2015;26:82–90.

Padma VN, Lalitha G, Shirony NP, et al. Effect of quercetin against lindane induced alterations in the serum and hepatic tissue lipids in Wistar rats. *Asian J Trop Biomed*. 2012;2:910–915.

Wan CW, Wong CN, Pin WK, et al. Chloerogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemics injected with a high-cholesterol diet. *Phytother Res*. 2013;27:545–551.

Snyder SM, Zhao B, Luo T, et al. Consumption of quercetin and quercetin-containing apple and cherry extracts affects blood glucose concentration, hepatic metabolism, and gene expression patterns in obese C57BL/6j high-fat-fed mice. *J Nutr*. 2016;146:1001–1007.

Leng L, Xiao Y, Mo Z, et al. Synergistic effect of phytochemicals on cholesterol metabolism and lipid accumulation in HepG2 cells. *BMC Complement Altern Med*. 2018;18:122. doi: 10.1186/s12906-018-2189-6.

Le Grimmellec C, Friedlander G, El Youndou EH, Zlatkine P, Giocondi MC. Membrane fluidity and transport properties in epithelia. *Kidney Int*. 1992;42:825–836.

Bastiaanse EML, Hold KM, Van der Laarse A. The effect of membrane cholesterol content on ion transport processes in plasma membranes. *Cardiovasc Res*. 1997;33:272–283.

Yeagle PL, Yeagle PL. The roles of cholesterol in the biology of cells. *The Structure of Biological Membranes*. 3rd ed.*Boca Raton: CRC Press*; 2012;119–129.

Balut C, Steels P, Radu M, Ameloot M, Dreische WV, Jans D. Membrane cholesterol extraction decreases Na+ transport in A6 renal epithelia. *Am J Physiol Cell Physiol*. 2006;290:C87–C94.

Grebowskii J, Krokosz A, Puchala M. Membrane fluidity and activity of ATPases in human erythrocytes under the influence of polyhydroxylated fullerenes. *Biochim Biophys Acta*. 2013;1828:244–248.

Krokosz A, Grebowski J, Chakravarti S, Dhillon NS. Activity of membrane ATPases in human erythrocytes under the influence of highly hydroxylated fullerene. *Regulation of Membrane Na+,K+-ATPase*. *Advances in Biochemistry in Health and Disease 15. Switzerland: Springer International Publishing*; 2016;159–172.

Garcia A, Lev B, Hossan KR, et al. Cholesterol depletion inhibits Na+,K+-ATPase activity in a near-native membrane environment. *J Biol Chem*. 2019;294:5956–5969.

Ma S, Jia R, Li D, et al. Targeting cellular metabolism chemosensitizes doxorubicin-resistant human breast adenocarcinoma cells. *BioMed Res Int*. 2015;2015:453986. doi: 10.1155/2015/453986.

Kumar N, Kant R, Maurya PK, et al. Concentration dependent effect of (+)-epicatechin on Na+,-K+-ATPase and Ca2+-ATPase inhibition induced by free radicals in hypertensive patients: Comparison with L-ascorbic acid. *Phytother Res*. 2002;26:1644–1647.
[95] Nicotera P, Moore M, Mirabelli F, et al. Inhibition of hepatocyte plasma membrane Ca\textsuperscript{2+}-ATPase activity by menadione metabolism and its restoration by thiols. FEBS Lett. 1985;181:149–153.

[96] Hanna AD, Lam A, Tham S, Duhlunt AE, Beard NA. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. Mol Pharmacol. 2014;85:438–449.

[97] Paterson CA, Zeng, J, Hussein Z, et al. Calcium ATPase activity and membrane structure in clear and cataractous human lenses. Curr Eye Res. 1997;16:333–338.

[98] Torlińska T, Grochowalska A. Age-related changes of Na\textsuperscript{+}, K\textsuperscript{+}-ATPase, Ca\textsuperscript{2+}-ATPase and Mg\textsuperscript{2+}-ATPase activities in rat brain synaptosomes. J Physiol Pharmacol. 2004;55:457–465.

[99] Patel V, Upaganlawar A, Zalawadia R, et al. Cardioprotective effect of lipid composition alters membrane Na\textsuperscript{+}, K\textsuperscript{+}–ATPase activity by menadione metabolism. Biophys J. 2007;93:–4236.

[100] Alexander RT, Beggs MR, Zamani R, et al. Ultrastructural and immunohistochemical localization of plasma membrane Ca\textsuperscript{2+}-ATPase in Ca\textsuperscript{2+}-transporting epithelia. Am J Physiol Renal Physiol. 2015;309:F604–F616.

[101] Sutherland E, Dixon BS, Leffert HL, et al. Biochemical localization of membrane proteins by the surrounding lipid environment. Biomolecules. 2019;9;513:10.3390/biom9100513.

[102] Sutherland E, Dixon BS, Leffert HL, et al. Biochemical localization of hepatic surface membrane Na\textsuperscript{+}, K\textsuperscript{+}-ATPase activity depends on membrane lipid fluidity. Proc Natl Acad Sci USA. 1988;85:8673–8677.

[103] Delamere NA, Paterson CA, Borchman D, et al. Calcium transport, Ca\textsuperscript{2+}-ATPase, and lipid order in rabbit ocular lens membranes. Am J Physiol. 1991;260 (Pt 1):C731–C737.

[104] Mozanti L, Rabini RA, Biagini G, et al. Changes in membrane fluidity and Na\textsuperscript{+}, K\textsuperscript{+}-ATPase activity during human trophoblast cell culture. Eur J Biochem. 1992;206:881–885.

[105] Wong-Ekkabut J, Xu Z, Triampo W, Tang IM, Tieleman DP, Glynn IM. Martonosi A. The Na, K-transporting adenosine triphosphatase. The Enzymes of Biological Membranes. 2nd edNew York, NY: Plenum; 1993;35–135.

[106] Vasic VM, Colovic BM, Krstic DZ. Mechanism of Na+/K+-ATPase and inhibition of Na\textsuperscript{+},K\textsuperscript{+}-ATPase activity induced by transient global cerebral ischemia in rats. J Nutr Biochem. 2011;22:921–928.

[107] Conrard L, Tyteca D. Regulation of membrane calcium transport proteins by the surrounding lipid environment. Biomolecules. 2019;9;513:10.3390/biom9100513.

[108] Vasic VM, Colovic BM, Krstic DZ. Mechanism of Na+/K+-ATPase and inhibition of Na\textsuperscript{+},K\textsuperscript{+}-ATPase activity induced by transient global cerebral ischemia in rats. J Nutr Biochem. 2011;22:921–928.

[109] Simão F, Matté A, Matté C, et al. Resveratrol prevents oxidative stress and inhibition of Na\textsuperscript{+},K\textsuperscript{+}-ATPase activity induced by transient global cerebral ischemia in rats. J Nutr Biochem. 2011;22:921–928.

[110] Strehler EE, Caride AJ, Filoteo AG, et al. Plasma membrane Ca\textsuperscript{2+} ATPases as dynamic regulators of cellular calcium handling. Ann N Y Acad Sci. 2007;1099:226–236.

[111] Di Leva F, Domi T, Fedrizzi L, Lim D, Carafoli E. The plasma membrane Ca\textsuperscript{2+}-ATPase of animal cells: structure, function and regulation. Arch Biochem Biophys. 2008;476:65–74.

[112] Doneen BA. High affinity calcium/magnesium ATPase in kidney of euryhaline Gillichthys mirabilis: kinetics, subcellular distribution and effect of salinity. Comp Biochem Physiol Physiol. 1993;106B:719–728.

[113] Streher EE, Caride AJ, Filoteo AG, et al. Plasma membrane Ca\textsuperscript{2+} ATPases as dynamic regulators of cellular calcium handling. Ann N Y Acad Sci. 2007;1099:226–236.

[114] Ortega A, Mas-Oliva J. Cholesterol effect on enzyme activity of the sarcoplasmal Ca\textsuperscript{2+},Mg\textsuperscript{2+}-ATPase from cardiac muscle. Biochim Biophys Acta. 1984;773:231–236.

[115] Tulenko TN, Bialecki R, Gleason M, Golatsky T, et al. Ion channels, membrane lipids and cholesterol: a role for membrane lipid domains in arterial function. Potassium Channels: Basic Function and Therapeutic Aspects. New York: Alan R Liss; 1990;187–203.

[116] Gleason MM, Medow MS, Tulenko TN. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res. 1991;69:216–227.

[117] Delgado-Coello B. Protein stability and the evolution of the cell membrane. Comp Biochem Physiol Physiol. 2007;146:207–213.

[118] Doneen BA. High affinity calcium/magnesium ATPase in kidney of euryhaline Gillichthys mirabilis: kinetics, subcellular distribution and effect of salinity. Comp Biochem Physiol Physiol. 1993;106B:719–728.

[119] Paterson CA, Zeng J, Husseini Z, et al. Calcium ATPase activity and inhibition of Na\textsuperscript{+},K\textsuperscript{+}-ATPase activity induced by transient global cerebral ischemia in rats. J Nutr Biochem. 2011;22:921–928.

[120] Doneen BA. High affinity calcium/magnesium ATPase in kidney of euryhaline Gillichthys mirabilis: kinetics, subcellular distribution and effect of salinity. Comp Biochem Physiol Physiol. 1993;106B:719–728.

[121] Doneen BA. High affinity calcium/magnesium ATPase in kidney of euryhaline Gillichthys mirabilis: kinetics, subcellular distribution and effect of salinity. Comp Biochem Physiol Physiol. 1993;106B:719–728.

[122] Vasic VM, Colovic BM, Krstic DZ. Mechanism of Na+/K+-ATPase and inhibition of Na\textsuperscript{+},K\textsuperscript{+}-ATPase activity induced by metal ions and complexes. Hem Ind. 2009;6:3–509.

[123] Gorlatch S, Carafoli E. The plasma membrane Ca\textsuperscript{2+} ATPase and the plasma membrane sodium calcium exchanger cooperate in the regulation of cell calcium. Cold Spring Harb Perspect Biol. 2011;3:1004168:10.1101/cshperspect.a1004168.

[124] Streher EE. Plasma membrane calcium ATPases as novel candidates for therapeutic agent development. J Pharm Pharm Sci. 2013;16:190–206.

[125] Penniston JT, Patandy R, Paszky K, et al. Apart from its known function, the plasma membrane Ca\textsuperscript{2+} ATPase can regulate Ca\textsuperscript{2+} signaling by controlling phosphatidylinositol 4,5-bisphosphate levels. J Cell Sci. 2014;127:72–84.

[126] Álvarez JAL, Murillo TGL, Nestor CAV. Najman S, et al. Epithelial Na\textsuperscript{+},K\textsuperscript{+}-ATPase—a sticky pump. Cell biology—New Insights. Croatia: IntechOpen; 2016;29–57.

[127] Brini M, Stanimirovic J, Panic A, Choi S, et al. Na+/K+-ATPase. Encyclopedia of Signaling Molecules. Switzerland: Springer; 2018; 3338–3343.